L’Oreal to Buy 10% Stake in Galderma

L’Oréal has announced it will be acquiring a 10% stake in Galderma.

The French beauty giant, whose rich skincare portfolio currently includes CeraVe, La Roche-Posay, and Vichy, will purchase the stake—for an undisclosed amount—from a group of major shareholders, including Sunshine SwissCo AG, a consortium led by Swedish private equity firm EQT, the Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd.

Alongside this acquisition, L’Oréal and Galderma have agreed to collaborate on new research and development (R&D) initiatives. This scientific partnership will focus on complementary research projects aimed at developing advanced, future-proof technologies with direct applications in the field of dermatology.

“I am very pleased to announce this strategic investment and partnership with Galderma,” said Nicolas Hieronimus, CEO of L’Oréal. “It marks an ambitious step for L’Oréal, and true to our mantra of ‘seize what is starting,’ it allows us to explore partnering in the fast-growing aesthetics market, a key adjacency to our own pure beauty play.”

The partnership aims to enable both companies to pursue new avenues and accelerate innovation in dermatology, targeting enhanced performance against the signs of skin aging. By leveraging complementary technologies, L’Oréal and Galderma plan to jointly develop new products aimed at expanding and enhancing their respective product portfolios.

Founded in 1981, Switzerland-based Galderma is a leader in dermatology, specialising in injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio includes the hyaluronic acid filler Restylane, the anti-wrinkle injection Azzalure, and the sensitive skincare brand Cetaphil, a major competitor to L’Oréal’s CeraVe.

“We are delighted to welcome L’Oréal as a new, long-term Galderma shareholder and see their investment as a sign of confidence in our strategy, track record and growth potential,” said Flemming Ørnskov, CEO of Galderma. “We look forward to pursuing scientific partnership opportunities together, for the benefit of the customers, patients and consumers we serve across the globe every day.”